Anxiety, Depression Med Use Linked to Increased Odds of PSA Testing
Researchers used 2018 data from the National Health Interview Survey to investigate the association.
Diagnosis & Disease Information
E-Cigarette Smoking History Tied to Increased Bladder, Lung Cancer Risk
Findings demonstrated that all smoking histories were tied to a higher prevalence of bladder and lung cancer.
Talabostat Plus Pembrolizumab Promising for mCRPC With Adenocarcinoma Phenotype
At a median follow-up of 12 weeks, results showed that the composite response rate was 23%.
Immune Checkpoint Inhibitor Combo Therapy Assessed in mRCC Patients With Poor Performance Status
Since patients with poor PS (≥2) were excluded from trials analyzing this new standard of care for mRCC treatment, the study aimed to assess the efficacy and safety of immune checkpoint combination therapy in this group of patients.
Bladder-Sparing Therapies for Localized Muscle-Invasive Bladder Cancer Compared
The real-world study compared the efficacy of neoadjuvant chemotherapy plus immunotherapy vs chemotherapy alone in patients with cT2-4bN0-3M0-1a pathological and imaging diagnosed MIBC.
Continued Enzalutamide Tx Beneficial in mCRPC Patients With Progressive Disease
The PRESIDE trial included 687 chemotherapy-naïve patients with mCRPC who had progressive disease while on androgen deprivation therapy or following bilateral orchiectomy.
Pembrolizumab Plus Lenvatinib Not Superior to Pembrolizumab Alone in Advanced Urothelial Carcinoma
The phase 3 LEAP-011 study evaluated pembrolizumab plus lenvatinib vs placebo in 441 adults with histologically confirmed, locally advanced or metastatic urothelial carcinoma.
Study Identifies Treatment Preferences in Advanced Renal Cell Carcinoma
The case-based study aimed to analyze the prescribing behaviors of community oncologists treating patients with aRCC.
Relugolix Effective, Safe in Black Men With Advanced Prostate Cancer
Study authors analyzed a total of 46 Black men with advanced prostate cancer enrolled in the phase 3 HERO study.
Statin Use Not Associated With Survival Benefits in mCRPC Patients
The analysis included 4919 patients, of which 19.7% (n=969) had received a lipophilic statin and 9.2% (n=452) had received a hydrophilic statin.
